Abstract
Regimes of treatment with cyclophosphamide-methotrexate-5-fluorouracil (CMF) or cyclophosphamide-adriamycin-5-fluorouracil(CAF) for breast cancer and 5-fluorouracil (5-FU) for prostate cancer may be used in patients with hormone-sensitive tumors after medical or surgical adrenalectomy or hypophy-sectomy (Craig-Henderson 1987). The anticancer drug hydroxyurea displayed a unique and marked toxicity in both pituitary- and adrenal-ablated animals (Vacca et al. 1985). The ability of intact, hypophysectomized, or adrenalectom-ized male adult rats to tolerate four anticancer drugs [busulfan (BU), carmustine (BCNU), cyclophosphamide (CY), and 5-FU] given according to the recommended treatment schedule and route in human cancer chemotherapy at doses corresponding to and 10–500 times greater than those employed per kilogram in humans (human therapeutic dose, Htd) (Salmon and Sartorelli 1987) was investigated. BU and BCNU are prescribed for neoplasm other than breast and prostate cancer but BU has caused “selective” pituitary insufficiency (Vivacqua et al. 1967) and BCNU may induce several hormonal changes due to pituitary stimulation (Kuo et al. 1975; Di Renzo et al. 1979).
Keywords
- Prostate Cancer
- Luteinizing Hormone
- Sudden Unexpected Death
- Pituitary Insufficiency
- Italian National Research Council
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Di Renzo GF, Schettini G, Annunziato L, Quattrone A, Preziosi P (1979) Modifiche di secrezioni endocrine indotte dalla somministrazione di farmaci antineoplastici. Giorn Ital Chemioter 26:255–261
Craig-Henderson I, Hayes DF, Come ST, Harris JR, Canellos G (1987) New agents and new medical treatments for advanced breast cancer. Sem Oncol 14:34–64
Kuo EYH, Esber JH, Taylor DJ, Bogden AE (1975) Effects of cancer chemotherapeutic agents on endocrine organs and serum levels of estrogens, progesterone, prolactin and luteinizing hormone. Cancer Res. 35:1975–1980
Salmon SE, Sartorelli AC (1987) Cancer chemotherapy. In: Katzung BE (ed) Basic and clinical pharmacology, 3rd ed. Lange, Los Altos, pp 665–701
Vacca M, De Gori N, del Carmine R, Navarra P, Preziosi P (1985) Replacement therapy against increased hydroxyurea toxicity in pituitary or adrenal ablated rats. Arch Toxicol Suppl 8:385–389
Vivacqua RJ, Haurant FJ, Ersley AJ (1967) “Selective” pituitary insufficiency secondary to busulphan. Ann Int Med 67:380–387
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag
About this paper
Cite this paper
Preziosi, P., Navarra, P., Vacca, M. (1988). Anticancer Drug Toxicity in the Absence of Hypophyseal or Adrenal Secretion. In: Chambers, P.L., Chambers, C.M., Dirheimer, G. (eds) The Target Organ and the Toxic Process. Archives of Toxicology, vol 12. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73113-6_51
Download citation
DOI: https://doi.org/10.1007/978-3-642-73113-6_51
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-18512-3
Online ISBN: 978-3-642-73113-6
eBook Packages: Springer Book Archive